Boston Scientific Corp. (NYSE:BSX)
The Company develops, manufactures & markets medical devices that are used in interventional cardiology, peripheral interventions, vascular surgery, electrophysiology, neurovascular intervention, oncology, endoscopy, urology, gynecology & neuromodulation.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
RockyXXII
(< 20)
Submitted: 11/9/2006 2:39:03 PM :
Start Price:
$16.11
BSX Score:
-64.75
they finally got the merger corrected
Recs
shtevied
(< 20)
Submitted: 10/24/2006 10:03:12 AM :
Start Price:
$15.98
BSX Score:
-65.56
Speculative, they will turn this around or be aquired cheap
Recs
alolio
(38.55)
Submitted: 10/20/2006 1:30:16 AM :
Start Price:
$16.10
BSX Score:
+65.95
Drowning in debt. High turnover for field employees. CRM division can't release products and continually becomes less competitive in the ICD market decline that they started. Yes, I am biased.
Recs
agentjj
(< 20)
Submitted: 10/12/2006 3:51:01 PM :
Start Price:
$15.44
BSX Score:
-64.54
can only go up
Recs
1jeshua
(32.22)
Submitted: 10/11/2006 2:40:19 AM :
Start Price:
$15.19
BSX Score:
-65.34
BSX has finally bottomed out, slow and steady climb back to $30.
Recs
tracyrees
(53.05)
Submitted: 10/9/2006 6:43:08 PM :
Start Price:
$14.55
BSX Score:
-63.60
Demographics are on their side. Aging boomers will drive revenue for many years to come. Guidant acquisition gives them great supplier pricing power. Revenue and margins will improve.
Recs
pvandevelde
(< 20)
Submitted: 10/6/2006 6:27:29 PM :
Start Price:
$14.76
BSX Score:
-64.20
Just bought it
Recs
davescharf
(60.69)
Submitted: 10/6/2006 12:19:10 AM :
Start Price:
$14.77
BSX Score:
+64.22
Too much debt due to Guidant acquisition and slowing CRM market will make this sotck languish for at least next 2 years.
Recs
dcrewsrn
(< 20)
Submitted: 10/4/2006 7:14:16 PM :
Start Price:
$14.55
BSX Score:
-63.60
Soldi product line in a growth field. Beaten down by temporary setbacks. Low current price represents a buying opportunity
Recs
dreamers123456
(< 20)
Submitted: 10/4/2006 11:19:24 AM :
Start Price:
$14.84
BSX Score:
-65.44
BSX will be doing well in the coming months even with JNJ's suit for 5 Billion which may not be successd in 5 to 10 years. However, Doctors had asked F to remove the "recall" from Guiden's Heart devise and recent FDA approved for BSX other produces which will increase it revenue to offset the lost of purchased Guiden.
Recs
cnbr1
(< 20)
Submitted: 10/4/2006 9:42:41 AM :
Start Price:
$14.74
BSX Score:
-65.62
Launch of Harmony, coated stents comeback when re-stenting factored, CRM increases based on obesity-induced arrhythmias
Recs
bigreenmountain
(76.88)
Submitted: 10/4/2006 4:40:02 AM :
Start Price:
$15.90
BSX Score:
-72.73
They've done everything but shoot BSX in the heart and install one of its own stints. It's at it's lowest PE ever and insiders are snatching it up. I say it's a bargain.
Recs
ValueStockMonger
(53.26)
Submitted: 10/4/2006 12:48:36 AM :
Start Price:
$14.74
BSX Score:
-65.62
Can it get any worse?
Recs
hives13
(< 20)
Submitted: 10/3/2006 12:45:46 PM :
Start Price:
$14.55
BSX Score:
-65.17
Too beaten down in a growing mktplaace. It will recover but now no one wants to touch it.
Recs
guitarpsych
(< 20)
Submitted: 9/27/2006 11:34:34 PM :
Start Price:
$14.79
BSX Score:
-65.06
Value play, out of favor stock and industry. But demographics are on cardiology device manufacturer's side and drug eluting stents are still in their infancy. Rock bottom pricing
Recs
rmale
(< 20)
Submitted: 9/22/2006 8:14:58 PM :
Start Price:
$14.71
BSX Score:
+66.85
Bought Boston Scientific in Spring 06. Bad move. I thought it was good value, but problems with the Guidant takeover have been compounded by problems with coated stents. Still I'm hanging on for the long term, meaning more than a couple of years.
Recs
ThadZ
(< 20)
Submitted: 9/22/2006 1:54:12 AM :
Start Price:
$14.69
BSX Score:
-66.55
The company has strong management and is actively partnering with the FDA. They will be the first and only player in their market that will have the ability to bundle Drug Eluting Stents, Pace Makers and Defibulators. This and a robust pipeline will give them a distinct competative advantage in the long run.
Recs
huestar
(73.96)
Submitted: 9/18/2006 10:23:41 PM :
Start Price:
$16.40
BSX Score:
-70.36
BSX is a great longstanding company that's poised for a turn around after being downtrodden for so long. Price looks great in my eyes.
Recs
ljm0655
(38.54)
Submitted: 8/25/2006 12:04:16 AM :
Start Price:
$17.12
BSX Score:
+74.40
Difficulty swallowing Guidant
Recs
ottodigbi
(< 20)
Submitted: 8/23/2006 10:24:23 AM :
Start Price:
$16.87
BSX Score:
-73.35
Bsx had a torrid time recently after it had a major recall of heart defibulator equipment supplied by Guident a company which it recently tookover.When Guident is properly bedded in bsx is set to outperform .Fundamentally sound -with plenty of cash in the balance sheet ,this stock is currently at a three year low . A great stock to buy at $16.5.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 181 - 200 of 201 : « Previous 5 6 7 8 9 10 11 Next »